Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
García-Benayas
Teresa
T
Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
Blanco
Francisco
F
de la Cruz
Juan José
JJ
Soriano
Vincent
V
González-Lahoz
Juan
J
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D016022:Case-Control Studies; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006801:Humans; D019344:Lactic Acid / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D018119:Stavudine / Q000009:adverse effects*; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D054303:HIV Reverse Transcriptase; D019344:Lactic Acid; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D000099227:Abacavir